Summary

Gilead Sciences, Inc. is a leading American biopharmaceutical company headquartered in Foster City, California, that specializes in researching, developing, and commercializing innovative medicines for life-threatening diseases. Founded in 1987, Gilead has grown into a global healthcare leader with approximately 17,600 employees worldwide. The company's primary therapeutic focus areas include HIV/AIDS, viral hepatitis (hepatitis B and C), oncology, inflammation, and respiratory diseases. Gilead is renowned for its groundbreaking antiviral therapies, including Sovaldi and Harvoni for hepatitis C, and its comprehensive portfolio of HIV treatments such as Truvada, Atripla, and Biktarvy. The company also developed Veklury (remdesivir) for COVID-19 treatment. Gilead operates as a publicly traded company on the NASDAQ (GILD) and is a component of both the Nasdaq-100 and S&P 100 indices. Through strategic acquisitions like Kite Pharma and Immunomedics, Gilead has expanded into cell therapy and oncology, demonstrating its commitment to advancing medical science and improving patient outcomes globally.

Job description

Key Responsibilities

Develop and implement global HEOR strategies and programs for Gilead inflammation products to inform, support and strengthen commercialization activities including clinical development, marketing and market access
Partner closely with cross-functional business partners to develop and support product value proposition to optimize access, reimbursement and uptake
Identify global HEOR evidence requirements and gaps; design, conduct and deliver studies, models and tools to support value demonstration and product differentiation for assigned indication
Provide HEOR input into clinical development programs
Partner with HEOR COE to guide development of PRO strategies; ensure PRO end points are included in product labeling and support product differentiation
Maintain up-to-date awareness of industry regulatory issues and research relationships with HEOR KOLs
Disseminate HEOR data and study results

Knowledge, Skills and Experience

12+ years of experience in the pharmaceutical industry and/or managed care, including direct experience in HEOR
Strong understanding of HEOR assessments and technical expertise in design and execution of HEOR studies and models
Experience in developing global and AMCP dossiers
Comprehensive understanding of US/global healthcare systems and reimbursement processes/decision making
Excellent oral and written communication skills and interpersonal skills
Experience in therapeutic area and/or US managed care
B.A. or B.S. required in life sciences, engineering or other related discipline; Advanced degree in HEOR-related field preferred

Requirements

12+ years of experience in the pharmaceutical industry and/or managed care, including direct experience in HEOR
Strong understanding of HEOR assessments and technical expertise in design and execution of HEOR studies and models
Experience in developing global and AMCP dossiers
Comprehensive understanding of US/global healthcare systems and reimbursement processes/decision making
Excellent oral and written communication skills and interpersonal skills
Experience in therapeutic area and/or US managed care
B.A. or B.S. required in life sciences, engineering or other related discipline
Advanced degree in HEOR-related field preferred

Benefits

Medical, Dental & Vision
Life Insurance
Paid Time Off
Annual Bonus
Stock-Based Long-Term Incentives

Company overview

Gilead Sciences, Inc. is a leading American biopharmaceutical company headquartered in Foster City, California, that specializes in researching, developing, and commercializing innovative medicines for life-threatening diseases. Founded in 1987, Gilead has grown into a global healthcare leader with approximately 17,600 employees worldwide. The company's primary therapeutic focus areas include HIV/AIDS, viral hepatitis (hepatitis B and C), oncology, inflammation, and respiratory diseases. Gilead is renowned for its groundbreaking antiviral therapies, including Sovaldi and Harvoni for hepatitis C, and its comprehensive portfolio of HIV treatments such as Truvada, Atripla, and Biktarvy. The company also developed Veklury (remdesivir) for COVID-19 treatment. Gilead operates as a publicly traded company on the NASDAQ (GILD) and is a component of both the Nasdaq-100 and S&P 100 indices. Through strategic acquisitions like Kite Pharma and Immunomedics, Gilead has expanded into cell therapy and oncology, demonstrating its commitment to advancing medical science and improving patient outcomes globally.